Subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects Annual Meeting GI 2016

Eric Van Cutsem, MD of University of Leuven discusses a subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects at ASCO GI 2016

Advertisement Single Between Content

clinical trial, received tas-102, tas-102

Advertisement Single Below Content

Subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects Annual Meeting GI 2016

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects Annual Meeting GI 2016

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia